Physician profile
David B Gerson
NPI 1992765010
$118,781.05
in general payments reported to CMS, 2019-2025
51 companies · $29K in 2025
The $29K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,978 · 2020: $1,650 · 2021: $26K · 2022: $33K · 2023: $12K · 2024: $16K · 2025: $29K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $46K · Food and Beverage: $7,417 · Consulting Fee: $2,250 · Travel and Lodging: $1,442.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $45,506.25 |
| Food and Beverage | $7,417.02 |
| Consulting Fee | $2,250.00 |
| Travel and Lodging | $1,442.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $101,806.17 | 2021-2025 | |
| Allergan, INC. | $2,150.96 | 2019-2021 | |
| Novo Nordisk INC | $1,783.98 | 2019-2025 | Wegovy, Ozempic, Saxenda |
| Glaxosmithkline, LLC. | $1,764.50 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $1,634.41 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $1,475.81 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $1,454.46 | 2019-2025 | Repatha, Otezla, Otezla |
| Pfizer INC. | $648.32 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $619.00 | 2019-2025 | Jardiance, Synjardy |
| Abbott Laboratories | $468.35 | 2022-2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $441.71 | 2019-2022 | |
| Astellas Pharma US INC | $433.27 | 2019-2025 | Veozah |
| Supernus Pharmaceuticals, INC. | $395.08 | 2021-2025 | Qelbree, Qelbree, Xyosted |
| Merck Sharp & Dohme LLC | $387.65 | 2019-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Esperion Therapeutics, INC. | $382.49 | 2021-2023 | Nexletol |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Gerson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.